Table 2.

Total Comments, Sentiments, and Rates of Categories From 2011 to 2017 for Adalimumab

Year	Total number of comments	Total number of coded sentiments	Sentiments
			Positive experience/supportive comment	Negative experience/adverse side-effect	Cost	Loss of efficacy	Diet	Drug administration
2011	103	98	27.2%	32.6%	6.5%	4.3%	2.2%	27.2%
2012	419	639	43.1%	17.7%	10.7%	2.9%	4.9%	18.8%
2013	359	482	31.3%	24.2%	4.1%	4.3%	4.1%	26.6%
2014	390	376	25.1%	17.3%	11.5%	0.7%	3.4%	36.3%
2015	458	487	43.4%	19.6%	2.5%	3.4%	2.9%	27.0%
2016	461	422	37.3%	9.9%	16.4%	0.8%	3.8%	28.2%
2017	530	492	33.7%	12.0%	12.2%	2.2%	1.7%	38.0%
Spearman’s rho, P-value 2011-2017	rho = 0.89, P = .01	rho = 0.29, P = .53	rho = 0.29, P = .53	rho = −0.79, P = .04	rho = 0.50, P = .25	rho = −0.58, P = .18	rho = −0.36, P = .43	rho = 0.64, P = .12
Spearman’s rho, P-value 2012-2017	rho = 0.83, P = .04	rho = −0.14, P = .79	rho = 0.03, P = .96	rho = −0.65, P = .16	rho = 0.54, P = .27	rho = −0.37, P = .47	rho = −0.83, P = .04	rho = 0.83, P = .04